Medicus Pharma Files Phase 2b/3 Trial Design For Teverelix
(RTTNews) - Tuesday, Medicus Pharma (MDCX) submitted a streamlined Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk.
(RTTNews) - Tuesday, Medicus Pharma (MDCX) submitted a streamlined Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk.